

BEST AVAILABLE COPY SEP 11 2006

TAFT, STETTINIUS & HOLLISTER LLP

425 WALNUT STREET, SUITE 1800

CINCINNATI, OHIO 45202-3957

NORTHERN KENTUCKY OFFICE
SUITE 340
1717 DIXIE HIGHWAY
COVINGTON, KENTUCKY 41011-4704
859-331-2838
513-381-2838
FAX: 513-381-0013

513-381-2838
FAX: 513-381-0205

www.taftlaw.com

COLUMBUS, OHIO OFFICE
21 EAST STATE STREET
COLUMBUS, OHIO 43215-4221
614-221-2838
FAX: 614-221-2007

CLEVELAND OHIO OFFICE
3500 BP TOWER
200 PUBLIC SQUARE
CLEVELAND, OHIO 44114-2302
216-241-2838
FAX: 216-241-3707

FAX TRANSMISSION

From: Sharon Shelton
Paralegal

Date: September 11, 2006

Direct Line: 513-357-9406

To: USPTO
Attn: Examiner Chen

Fax No. 571-273-8300

Confirmation No.

No. of Pages (including this cover page) four (4)

CONFIDENTIALITY NOTICE

This message may constitute privileged attorney-client communication or attorney work product, and unauthorized use or disclosure is prohibited. If you are not the intended recipient of this message, please advise us by calling collect at (513) 381-2838 and forward the document to us by mail at the address above.

If you do not receive all pages satisfactorily, please call (513) 381-2838, ext 173.
To send to any of our automatic machines, please dial direct: (513) 381-0205.

Message: DELIVER TO EXAMINER SHIN-LIN CHEN

Applicant : Robbins, Jeffrey
Filed : March 11, 2004
Serial No. : 10/798,037
Title : CARDIAC-PREFERRED GENETIC ALTERATION OF TRANSGENIC RABBITS
Docket No. : CHM02-GN054
Examiner : Chen, Shin-Lin
Art Unit : 1632

See attached Response to Election/Restriction Requirement in the above-referenced matter.

Sent By: _____ Time: _____

CMR: 70792

RECEIVED
CENTRAL FAX CENTER

SEP 11 2006

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office (Fax
No. (571) 273-8300) on:

9/11/2006

Date

Sharon Shelton
Sharon SheltonPATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Applicant : Robbins, Jeffrey
Serial No. : 10/798,037
Filed : March 11, 2004
Title : CARDIAC-PREFERRED GENETIC ALTERATION OF
TRANSGENIC RABBITS
Docket No. : CHM02 GN054
Examiner : Shin-Lin Chen
Art Unit : 1632

Hon. Commissioner for Patents
Alexandria, VA 22313

Dear Sir:

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

This paper is filed in response to the Election/Restriction Requirement Office action
mailed on July 10, 2006 having a period of response extending through and including September
11, 2006.

REMARKS

The July 10, 2006 Office action indicates that pending claims, 1-49, are subject to a
restriction or election requirement.

Election

Serial No. 10/798,037

CARDIAC-PREFERRED GENETIC ALTERATION OF TRANSGENIC RABBITS

Docket No. : CHM02-GN054

RECEIVED
CENTRAL FAX CENTER

SEP 11 2006

As indicated on Page 2 of the July 10 Office Action, it is alleged that the application contains claims directed to five patentably distinct inventions:

Group I: Claims 1-9 drawn to an animal cell stably transformed with an expression cassette comprising a promoter having the nucleotide sequence set forth in SEQ ID NO:1 or 2 or variants thereof operably linked to a heterologous nucleotide sequence.

Group II: Claims 10-26 and 35-39, drawn to a transgenic rabbit or animal stably transformed with an expression cassette comprising a promoter having the nucleotide sequence set forth in SEQ ID NO:1 or 2 or variants thereof operably linked to a heterologous nucleotide sequence.

Group III: Claims 27-33 and 40-42, drawn to methods of altering expression of a heterologous nucleotide sequence in an animal comprising providing a transgenic animal with a promoter having the nucleotide sequence set forth in SEQ ID NO:1 or 2 or variants thereof operably linked to a heterologous nucleotide sequence and determining expression levels of the heterologous nucleotide sequence, kits for performing these methods comprising a transgenic rabbit of the invention, and kits comprising a transgenic rabbit of the invention.

Group IV: Claims 34 and 44-49, drawn to methods of identifying anti-cardiopathic compounds involving providing transgenic rabbits, administering a compound of interest to a first rabbit and monitoring a cardiopathic phenotype in the first rabbit and an untreated second rabbit, kits for performing methods of identifying anti-cardiopathic compounds, and kits for altering an animal's susceptibility to a cardiopathy.

Group V: Claim 43 drawn to a kit for performing a method of altering expression of a heterologous nucleotide sequence in an animal said kit comprising at least one expression cassette comprising a promoter having the nucleotide sequence set forth in SEQ ID NO:1 or 2 or variants thereof.

Applicant elects to prosecute the claims 10-26 and 35-39 corresponding to Group II, without traverse.

If the Examiner holds that the instant election is proper, cancellation of claims 1-9, 27-34, and 40-49 will follow the first Office action on the merits. Favorable consideration of the elected claims is respectfully requested. The Commissioner is hereby authorized to charge any

Election

Serial No. 10/798,037


CARDIAC-PREFERRED GENETIC ALTERATION OF TRANSGENIC RABBITS

Docket No. : CHM02-GN054

RECEIVED
CENTRAL FAX CENTER
SEP 11 2006

additional fees that may be required by this paper, or to credit any overpayment to Deposit
Account 50-3072. If the Examiner wishes to discuss any aspect of this response, do not hesitate
to contact the undersigned at the telephone number provided below.

Respectfully submitted,



David A. Mancino
Reg. No. 39,289

030074
Taft, Stettinius & Hollister LLP
425 Walnut Street; Suite 1800
Cincinnati, Ohio 45202-3957
Direct Line: 513-357-9331
Facsimile: 513-381-0205
mancino@taftlaw.com

{W0784399.1}3